Champions Oncology (CSBR) Asset Utilization Ratio (2011 - 2026)
Champions Oncology (CSBR) recorded quarterly Asset Utilization Ratio of 1.98 in Q1 2026, up 2.73% quarter-over-quarter from 1.92 in Q4 2025, and down 5.73% on a YoY basis from 2.1 in Q1 2025.
Champions Oncology (CSBR) Asset Utilization Ratio (2011 - 2026) Analysis & Trends
Champions Oncology's Asset Utilization Ratio history runs 16 years deep, the most recent figure standing at 1.98 for Q1 2026.
- In Q1 2026, Asset Utilization Ratio fell 5.73% year-over-year to 1.98; the TTM figure through Jan 2026 stood at 1.98 (down 5.73% YoY), while the FY2025 annual figure was 1.95, up 17.36% from the prior year.
- Asset Utilization Ratio was 1.98 for Q1 2026 at Champions Oncology, up from 1.92 in the prior quarter.
- In the past five years, Asset Utilization Ratio ranged from a high of 2.14 in Q4 2024 to a low of 1.42 in Q2 2022.
- Historically, Asset Utilization Ratio has averaged 1.75 across 5 years, with a median of 1.79 in 2024.
- The sharpest annual moves came in 2024 and 2025: Asset Utilization Ratio climbed 24.34% in 2024, then dropped 10.59% in 2025.
- A 5-year view of Asset Utilization Ratio shows it stood at 1.53 in 2022, then grew by 12.32% to 1.72 in 2023, then rose by 24.34% to 2.14 in 2024, then decreased by 9.87% to 1.92 in 2025, then climbed by 2.73% to 1.98 in 2026.
- The last three Asset Utilization Ratio figures came in at 1.98 (Q1 2026), 1.92 (Q4 2025), and 1.81 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | 0.55 |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 0.60 |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | 1,422.00 |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 0.47 |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | Champions Oncology | 78.46 Mn | 71.46 Mn | 13.89 Mn | 1.98 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jan 31, 2026 | 1.98 |
| Oct 31, 2025 | 1.92 |
| Jul 31, 2025 | 1.81 |
| Apr 30, 2025 | 1.81 |
| Jan 31, 2025 | 2.10 |
| Oct 31, 2024 | 2.14 |
| Jul 31, 2024 | 2.02 |
| Apr 30, 2024 | 1.90 |
| Jan 31, 2024 | 1.79 |
| Oct 31, 2023 | 1.72 |
| Jul 31, 2023 | 1.64 |
| Apr 30, 2023 | 1.53 |
| Jan 31, 2023 | 1.48 |
| Oct 31, 2022 | 1.53 |
| Jul 31, 2022 | 1.48 |
| Apr 30, 2022 | 1.42 |
| Jan 31, 2022 | 1.49 |
| Oct 31, 2021 | 1.55 |
| Jul 31, 2021 | 1.53 |
| Apr 30, 2021 | 1.55 |